Summary BioTime, Inc. (BioTime) is a biotechnology company with focus on regenerative medicine and plasma volume expanders. The company's Hextend is a blood plasma volume expander used for the treatment of hypovolemia in surgery, emergency trauma treatment, and other applications. The company is also developing Renevia to facilitate cell transplantation; AST-VAC1 autologous (patient-specific) cancer vaccine; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); AST-OPC1 for spinal cord injury rehabilitation; HyStem hydrogel products; and mobile health software products. The company's products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. The company's products are developed on its pluripotent stem technology based on induced pluripotent stem (iPS) cells and human embryonic stem (hES) cells. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope: - The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments - The report analyzes all pipeline products in development for the company BioTime, Inc. - The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) - The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date - The report provides detailed description of products in development, technical specification and functions - The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date. Reasons to Buy: - Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape - Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio - To formulate effective Research & Development strategies - Develop market-entry and market expansion strategies - Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc - Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 BioTime, Inc. Company Snapshot 6 BioTime, Inc. Company Overview 6 BioTime, Inc. Pipeline Products and Clinical Trials Overview 7 BioTime, Inc. - Pipeline Analysis Overview 9 Business Description 9 Key Facts 10 BioTime, Inc. - Major Products and Services 11 BioTime, Inc. Pipeline Products by Development Stage 12 BioTime, Inc. Clinical Trials by Trial Status 14 BioTime, Inc. Pipeline Products Overview 16 BioTime Films 16 BioTime Films Product Overview 16 BioTime Sponges 17 BioTime Sponges Product Overview 17 HyStem Renevia 18 HyStem Renevia Product Overview 18 HyStem Renevia Clinical Trial 19 HyStem-Spine 20 HyStem-Spine Product Overview 20 HyStem-Tendon 21 HyStem-Tendon Product Overview 21 PanC-Dx - Bladder Cancer 22 PanC-Dx - Bladder Cancer Product Overview 22 PanC-Dx - Bladder Cancer Clinical Trial 23 PanC-Dx - Breast Cancer 24 PanC-Dx - Breast Cancer Product Overview 24 PanC-Dx - Breast Cancer Clinical Trial 25 PanC-Dx - Colon Cancer 26 PanC-Dx - Colon Cancer Product Overview 26 PanC-Dx - Lung Cancer 27 PanC-Dx - Lung Cancer Product Overview 27 PanC-Dx - Prostate Cancer 28 PanC-Dx - Prostate Cancer Product Overview 28 ReGlyde 29 ReGlyde Product Overview 29 BioTime, Inc. - Key Competitors 30 BioTime, Inc. - Key Employees 31 BioTime, Inc. - Key Employee Biographies 32 BioTime, Inc. - Locations And Subsidiaries 33 Head Office 33 Other Locations & Subsidiaries 33 Recent Developments 35 BioTime, Inc., Recent Developments 35 Dec 30, 2015: BioTime Announces "When-Issued" Trading of Subsidiary OncoCyte in Connection With Planned Distribution 35 Nov 24, 2015: LifeMap Solutions Appoints Robert W. Peabody Chief Financial Officer 35 Nov 18, 2015: BioTime Announces the Appointment of Life Sciences Industry Veteran Russell Skibsted as Chief Financial Officer 35 Nov 09, 2015: BioTime Reports Third Quarter 2015 Results and Recent Corporate Accomplishments 36 Nov 04, 2015: LifeMap Sciences, a Subsidiary of BioTime, and Lab7 Systems Announce Partnership and Launch of Integrated NGS Analysis Solution 39 Oct 19, 2015: Adi Mohanty Joins Michael D. West, PhD, as Co-CEO of BioTime 40 Sep 29, 2015: LifeMap Solutions Announce Initial Results for Asthma Health App and New Features to Enhance Clinical Impact 41 Sep 29, 2015: Mount Sinai and LifeMap Solutions Announce Initial Results for Asthma Health App and New Features to Enhance Clinical Impact 41 Sep 14, 2015: BioTime Subsidiary OncoCyte Appoints Cavan Redmond to its Board of Directors 42 Sep 02, 2015: ESI BIO - A Division of BioTime Launches New Research Technology Platform, VascuNet Pericyte Co-Culture Assay 42 Appendix 44 Methodology 44 About GlobalData 44 Contact Us 44 Disclaimer 44
List of Tables
BioTime, Inc. Pipeline Products and Clinical Trials Overview 7 BioTime, Inc. Pipeline Products by Equipment Type 7 BioTime, Inc. Pipeline Products by Indication 8 BioTime, Inc. Clinical Trials by Trial Status 8 BioTime, Inc., Key Facts 10 BioTime, Inc., Major Products and Services 11 BioTime, Inc. Number of Pipeline Products by Development Stage 12 BioTime, Inc. Pipeline Products Summary by Development Stage 13 BioTime, Inc. Clinical Trials by Trial Status 14 BioTime, Inc. Clinical Trials Summary 15 BioTime Films - Product Status 16 BioTime Films - Product Description 16 BioTime Sponges - Product Status 17 BioTime Sponges - Product Description 17 HyStem Renevia - Product Status 18 HyStem Renevia - Product Description 18 HyStem Renevia - Pivotal Clinical Trial of Renevia for HIV-associated Lipoatrophy 19 HyStem-Spine - Product Status 20 HyStem-Spine - Product Description 20 HyStem-Tendon - Product Status 21 HyStem-Tendon - Product Description 21 PanC-Dx - Bladder Cancer - Product Status 22 PanC-Dx - Bladder Cancer - Product Description 22 PanC-Dx - Bladder Cancer - An Observational Clinical Study to Validate the Performance of OncoCyte's Proprietary Diagnostic Technology 23 PanC-Dx - Breast Cancer - Product Status 24 PanC-Dx - Breast Cancer - Product Description 24 PanC-Dx - Breast Cancer - Clinical Study of PanC-Dx for Breast Cancer and Other Types of Human Cancers 25 PanC-Dx - Colon Cancer - Product Status 26 PanC-Dx - Colon Cancer - Product Description 26 PanC-Dx - Lung Cancer - Product Status 27 PanC-Dx - Lung Cancer - Product Description 27 PanC-Dx - Prostate Cancer - Product Status 28 PanC-Dx - Prostate Cancer - Product Description 28 ReGlyde - Product Status 29 ReGlyde - Product Description 29 BioTime, Inc., Key Employees 31 BioTime, Inc., Key Employee Biographies 32 BioTime, Inc., Subsidiaries 33
List of Figures
BioTime, Inc. Pipeline Products by Equipment Type 8 BioTime, Inc. Pipeline Products by Development Stage 12 BioTime, Inc. Clinical Trials by Trial Status 14
Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive tRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Global aerosol propellants market is anticipated to reach USD 24.8 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing popularity of personal care and cosmetics products such as hair sprays, deodorants and shaving creamRead More...
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.